Sign In
Buy LNTH
$101.11
-0.0800 (-0.0791%)
At Close: Aug 04, 2026
4 Stocks With Solid Net Profit Margin to Boost Portfolio Return
07:32am, Friday, 03'rd Feb 2023
Let's take a look at four top-ranked stocks - Arch Resources (ARCH), International Game Technology (IGT), Old Second Bancorp (OSBC) and Lantheus Holdings (LNTH) - with solid net profit margins.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:33am, Wednesday, 01'st Feb 2023
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Wednesday, 25'th Jan 2023
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?
01:33pm, Tuesday, 24'th Jan 2023
Lantheus Holdings (LNTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 83.92%
11:17am, Tuesday, 24'th Jan 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable,
Down -8.54% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)
11:17am, Friday, 06'th Jan 2023
The heavy selling pressure might have exhausted for Lantheus Holdings (LNTH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street a
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
08:30am, Wednesday, 04'th Jan 2023
NORTH BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiothera
Down -21.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)
11:17am, Thursday, 29'th Dec 2022
Lantheus Holdings (LNTH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e
Is Lantheus (LNTH) Outperforming Other Medical Stocks This Year?
11:16am, Tuesday, 27'th Dec 2022
Here is how Lantheus Holdings (LNTH) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
3 Medical Stocks Creating Wealth Despite Macro Challenges
10:32am, Wednesday, 21'st Dec 2022
Here we discuss three stocks - CAH, LNTH and TMDX - that have been creating wealth for their investors in 2022 as several competitors faltered amid macro challenges. Will the trend continue?
Lantheus Holdings (LNTH) Loses 10.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:17am, Friday, 09'th Dec 2022
Lantheus Holdings (LNTH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in
Lantheus: Sell Thesis Missing These Key Factors
01:28am, Tuesday, 29'th Nov 2022
Quarterly revenue grew 134% YoY to $239.3mm, driven by strengths across the portfolio. Management raised Q4 and FY22 guidance to the upside from the top-bottom lines.
3 Medical Products Stocks Navigating Industry Challenges (Revised)
08:17am, Thursday, 24'th Nov 2022
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-pois
3 Stocks That Could Be the Next Big M&A Targets
02:16pm, Friday, 18'th Nov 2022
Bloomberg Law recently discussed the global mergers and acquisitions (M&A) market. Their analysis pointed out that even though the 2022 M&A volume is down from a record number of transactions in 2021,
3 Medical Products Stocks Navigating Industry Challenges
09:10am, Friday, 18'th Nov 2022
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-pois
